BioSpace News Archive

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel.

Rapid Medical, a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER™13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming conferences.

Senseonics Holdings, Inc. (NYSE American: SENS) today announced that it plans to release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022.

AACC 2022 Open Lab Solutions, Inc., is announcing the formation of a new division, AMCAR Scientific, that will focus on an expanding product line of plastic consumables used in the medical industry.

Aisa Pharma, Inc. today announced that the Data Safety Monitoring Board (DSMB) for the RECONNOITER Phase 2 study of Aisa’s Profervia® once-daily novel, oral calcium-channel antagonist has met and unanimously recommended continuing to the next stage in the trial and approved a go-forward dose level.

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it has priced an underwritten public offering of 8,140,000 American Depositary Shares (“ADSs”), each representing two ordinary shares, at a public offering price of $43.00 per ADS.

Exo (pronounced “echo”), a pioneering health information and medical devices company, today announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use.

Menarini Silicon Biosystems Inc, a US company part of the Menarini Group and DIESSE Diagnostica Senese Società Benefit S.p.A. announced at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.

In order to bring new cutting-edge research models to the market to accelerate the development of novel therapeutics for a host of unmet medical needs, particularly in immuno-oncology, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has entered into a strategic license agreement with Charles River Laboratories, Inc. for exclusive distribution of its next generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America.